3:12
Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trneny
2:03
Trial updates in NHL: RELEVANCE, polatuzumab, TRANSCEND-NHL-001 & Hu5F9-G4
Nathan Fowler
1:32
Choosing the best treatment for your follicular lymphoma patient
Nathan Fowler
3:53
Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma
Nathan Fowler
2:28
Preventing early disease progression in follicular lymphoma
John Seymour
3:21
RELEVANCE study: the R-squared regimen for follicular lymphoma
Wojciech Jurczak
2:27
Challenges within follicular lymphoma treatment
Wendy Osborne
1:34
Molecular-guided treatment of B-cell lymphomas
Jude Fitzgibbon
1:42
Precision medicine for B-cell lymphomas
Jude Fitzgibbon
6:38
Follicular lymphoma: is RELEVANCE relevant?
Frank Morschhauser
3:43
Predictors of outcome for follicular lymphoma
Anna Schuh
2:01
Safety data for the PI3Kδ inhibitor umbralisib for lymphoid malignancies
Susan O’Brien
2:00
Long-term follow-up results of the ZUMA-1 trial of anti-CD19 CAR T-cells for non-Hodgkin lymphoma
Sattva Neelapu
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al.
2:31
Chemotherapy-free approaches in CLL, follicular lymphoma and DLBCL
Christian Buske
5:37
Key abstracts being presented at ASH 2017
Anas Younes
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals